Answers are grounded in this paper and cite their sources.
Central venous thrombosis after central venous catheter indwelling is an underestimated complication. There are far fewer reports on the clinical significance of catheter-related thrombosis in septic adults, than in hemato-oncologic, pediatric, and hemodialytic patients. Sepsis has impacts on the systemic coagulation mechanism that differ from the above diseases, and potentiates thrombosis formation. Severe catheter-related thrombosis manifesting as central venous occlusion is very rare. The safety of warfarin, thrombolytic agents, and recombinant human activated protein C in septic patients remains unclear; therefore, the treatment of choice is not well established. With the increased sepsis incidence and widespread use of central venous catheters in these patients, catheter-related thrombosis should be given more attention and discussion. We report a septic shock patient with severe femoral venous thrombosis after central venous catheter implantation. A lower extremity duplex ultrasonogram confirmed the diagnosis. The patient was treated with dalteparin subcutaneously. The endovascular thrombosis resolved completely 7 days later. This treatment experience suggests that dalteparin is safe and cost-effective for catheter-related thrombosis.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: